{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:04:48Z","timestamp":1791975888981,"version":"4.4.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>According to the latest WHO classification of hematopoietic malignancies, myeloid and lymphoid neoplasms with eosinophilia and gene rearrangements include three specific rare diseases and one provisional entity. Myeloid\/lymphoid neoplasms with platelet-derived growth factor receptor alpha (PDGFRA) rearrangements are the most frequent of these disorders and are usually present in adult males with a median age of the late 40s. Patients usually have chronic eosinophilic leukemia but can occasionally manifest as acute myeloid leukemia or extramedullary T- or B-lineage lymphoblastic lymphoma. We report a case of a previously healthy 2-year-old girl who presented with a right supraorbital swelling with no associated lymphadenopathy. Peripheral blood smear evaluation at initial presentation revealed microcytic hypochromic red blood cells and leukocytosis with marked eosinophilia, occasional myelocytes, and occasional blasts. Whole-body CT scans and PET scans revealed hypermetabolic potentially lymphomatous mass in the superior medial aspect of the right orbit in addition to splenomegaly but no evidence of hypermetabolic mediastinal, hilar, abdominal, or pelvic lymph nodes. Bone marrow aspirate and biopsy revealed hypercellular bone marrow with quantitatively decreased erythroid precursors and increased granulocytic precursors with 60% of the cells being eosinophilic cells in different stages of maturation. The diagnosis of myeloid neoplasm with eosinophilia and rearrangement of PDGFRA was made following confirmation by fluorescence <jats:italic>in situ<\/jats:italic> hybridization (FISH) test for <jats:italic>FIP1L1-PDGFRA<\/jats:italic> gene fusion. An incisional biopsy of the supraorbital mass revealed B-cell lymphoblastic lymphoma (B-LBL). FISH test for <jats:italic>FIP1L1-PDGFRA<\/jats:italic> gene fusion was positive in 70% of the cells studied. Thus, the final diagnosis was B-cell lymphoblastic lymphoma arising in the setting of myeloid\/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement. The patient was started on imatinib with concomitant therapy for B-LBL per the Children Oncology Group (COG) standard therapy for localized B-LBL and demonstrated a favorable outcome in the 2.5-year follow-up period. To our knowledge, this is the first pediatric case of myeloid\/lymphoid neoplasm with PDGFRA rearrangement presenting with synchronous myeloproliferative disease and B-LBL. We present our diagnostic and management approach of this patient and review prior relevant pediatric cases of myeloid\/lymphoid neoplasms with PDGFRA rearrangement.<\/jats:p>","DOI":"10.3389\/fped.2022.1059527","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T07:04:25Z","timestamp":1671001465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Pediatric myeloid\/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Reem","family":"Akiely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Almasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidal","family":"Almasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Abu-Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition)","author":"Swerdlow","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","article-title":"Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2","volume":"155","author":"Pozdnyakova","year":"2021","journal-title":"Am J Clin Pathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1309\/AJCPMORR5Z2IKCEM","article-title":"Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1","volume":"144","author":"Vega","year":"2015","journal-title":"Am J Clin Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/01.mph.0000193467.06938.77","article-title":"Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement","volume":"27","author":"Rives","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/pbc.22655","article-title":"Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate","volume":"55","author":"Rathe","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/pbc.25199","article-title":"Relapse of myeloid neoplasm with eosinophilia and PDGFRA rearrangement after imatinib discontinuation in a pediatric patient","volume":"61","author":"Rathe","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2141.2010.08394.x","article-title":"Molecular characterization of paediatric idiopathic hypereosinophilia","volume":"151","author":"Rapanotti","year":"2010","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/MPH.0b013e31827e6386","article-title":"FIP1L1-PDGFRalpha-positive Hypereosinophilic syndrome in childhood: a case report and review of literature","volume":"36","author":"Farruggia","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/jdv.12416","article-title":"Newly identified phenotypes in a FIP1L1\/PDGFRA-associated paediatric HES patient: thrombocytosis, mHPA, young stroke and blindness","volume":"29","author":"Zeng","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cancergen.2017.07.007","article-title":"A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia\/lymphoma without eosinophilia","author":"Oberley","year":"2017","journal-title":"Cancer Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/MPH.0000000000001446","article-title":"Myeloid neoplasm with eosinophilia and FIP1L1-PDGFRA rearrangement treated with imatinib mesylate: a pediatric case with long-term follow-up","volume":"41","author":"Srinivasan","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e227653","DOI":"10.1136\/bcr-2018-227653","article-title":"Hypereosinophilia and severe bone disease in an African child: an unexpected diagnosis","volume":"12","author":"Bota","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1097\/HS9.0000000000000486","article-title":"Sustained complete molecular remission with imatinib monotherapy in a child presenting with blast phase FIP1L1-PDGFRA-associated myeloid neoplasm with eosinophilia","volume":"4","author":"Jain","year":"2020","journal-title":"Hemasphere"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1710","DOI":"10.1002\/cnr2.1710","article-title":"Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature","volume":"5","author":"Voeller","year":"2022","journal-title":"Cancer Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpeds.2004.09.014","article-title":"Pediatric hypereosinophilic syndrome (HES) differs from adult HES","volume":"146","author":"Katz","year":"2005","journal-title":"J Pediatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00280-008-0858-8","article-title":"Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose","volume":"63","author":"Breccia","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1059527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T07:04:28Z","timestamp":1671001468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1059527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":18,"alternative-id":["10.3389\/fped.2022.1059527"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1059527","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1059527"}}